Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA, Porteous ME, Dunlop MG, Campbell H
published in the Bulletin of Experimental Biology and Medicine observed telomerase activation in human somatic cells treated with Epithalon
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
Use bacteriostatic water rather than sterile water to achieve this shelf life
She also has experience as a Clinical Instructor at the University of Tennessee, teaching physical health assessment, medical-surgical and community nursing, and supervising and guiding nursing undergraduate students
Conventional natural killer (NK) cells, a kind of ILC, can produce IFN-, TNF- and granulocytemacrophage colony stimulating factor (GM-CSF) to participate in the immune response [49]
